Gyriform infiltration as imaging biomarker for molecular glioblastomas.
IDH-wild-type astrocytoma
Imaging marker
Molecular glioblastoma
T2-FLAIR
TERT
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
02
02
2022
accepted:
23
03
2022
pubmed:
3
4
2022
medline:
10
5
2022
entrez:
2
4
2022
Statut:
ppublish
Résumé
Molecular glioblastomas (i.e. without the histological but with the molecular characteristics of IDH-wild-type glioblastoma) frequently lack contrast enhancement, which can wrongly lead to suspect a lower-grade glioma. Herein, we aimed to assess the diagnostic value of gyriform infiltration as an imaging marker for molecular glioblastomas. Two independent investigators reviewed the MRI scans from patients with newly diagnosed gliomas for the presence of a gyriform infiltration defined as an elective cortical hypersignal on MRI FLAIR sequence. Diagnostic test performance of this sign for the diagnosis of molecular glioblastoma were calculated. A total of 426 patients were included, corresponding to 31 molecular glioblastoma, 294 IDH-wild-type glioblastoma, 50 IDH-mutant astrocytoma, and 51 IDH-mutant 1p19q-codeleted oligodendroglioma. A gyriform infiltration was observed in 16/31 (52%) molecular glioblastoma, 40/294 (14%) IDH-wild-type glioblastoma, and none of the IDH-mutant glioma. All the 56 gyriform-infiltration-positive tumors were IDH-wild-type and all but two had a TERT promoter mutation. The inter-rater agreement was good (κ = 0.69, p < 0.001). The sensitivity, specificity, positive predictive value and negative predictive value of the presence of a gyriform infiltration for the diagnosis of molecular glioblastoma were 52%, 90%, 29%, 96%, respectively. The median overall survival was better for gyriform-infiltration-negative patients compared to gyriform-infiltration-positive patients in the whole series and in patients with non-enhancing lesions (n = 95) (25.6 vs 16.9 months, p = 0.005 and 20.2 months vs not reached, p < 0.001). Gyriform infiltration is a specific imaging marker of molecular glioblastomas that can help distinguishing these tumors from IDH-mutant lower-grade gliomas.
Sections du résumé
BACKGROUND
BACKGROUND
Molecular glioblastomas (i.e. without the histological but with the molecular characteristics of IDH-wild-type glioblastoma) frequently lack contrast enhancement, which can wrongly lead to suspect a lower-grade glioma. Herein, we aimed to assess the diagnostic value of gyriform infiltration as an imaging marker for molecular glioblastomas.
METHODS
METHODS
Two independent investigators reviewed the MRI scans from patients with newly diagnosed gliomas for the presence of a gyriform infiltration defined as an elective cortical hypersignal on MRI FLAIR sequence. Diagnostic test performance of this sign for the diagnosis of molecular glioblastoma were calculated.
RESULTS
RESULTS
A total of 426 patients were included, corresponding to 31 molecular glioblastoma, 294 IDH-wild-type glioblastoma, 50 IDH-mutant astrocytoma, and 51 IDH-mutant 1p19q-codeleted oligodendroglioma. A gyriform infiltration was observed in 16/31 (52%) molecular glioblastoma, 40/294 (14%) IDH-wild-type glioblastoma, and none of the IDH-mutant glioma. All the 56 gyriform-infiltration-positive tumors were IDH-wild-type and all but two had a TERT promoter mutation. The inter-rater agreement was good (κ = 0.69, p < 0.001). The sensitivity, specificity, positive predictive value and negative predictive value of the presence of a gyriform infiltration for the diagnosis of molecular glioblastoma were 52%, 90%, 29%, 96%, respectively. The median overall survival was better for gyriform-infiltration-negative patients compared to gyriform-infiltration-positive patients in the whole series and in patients with non-enhancing lesions (n = 95) (25.6 vs 16.9 months, p = 0.005 and 20.2 months vs not reached, p < 0.001).
CONCLUSION
CONCLUSIONS
Gyriform infiltration is a specific imaging marker of molecular glioblastomas that can help distinguishing these tumors from IDH-mutant lower-grade gliomas.
Identifiants
pubmed: 35364762
doi: 10.1007/s11060-022-03995-9
pii: 10.1007/s11060-022-03995-9
doi:
Substances chimiques
Biomarkers
0
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
511-521Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106
doi: 10.1093/neuonc/noab106
pubmed: 34185076
Louis DN, Wesseling P, Aldape K et al (2020) cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol 30:844–856. https://doi.org/10.1111/bpa.12832
doi: 10.1111/bpa.12832
pubmed: 32307792
pmcid: 8018152
Stichel D, Ebrahimi A, Reuss D et al (2018) Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136:793–803. https://doi.org/10.1007/s00401-018-1905-0
doi: 10.1007/s00401-018-1905-0
pubmed: 30187121
Izquierdo C, Barritault M, Poncet D et al (2019) Radiological characteristics and natural history of adult IDH-wildtype astrocytomas with TERT promoter mutations. Neurosurgery 85:E448–E456. https://doi.org/10.1093/neuros/nyy513
doi: 10.1093/neuros/nyy513
pubmed: 30407589
Metellus P, Coulibaly B, Colin C et al (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719–729. https://doi.org/10.1007/s00401-010-0777-8
doi: 10.1007/s00401-010-0777-8
pubmed: 21080178
Juratli TA, Tummala SS, Riedl A et al (2019) Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. J Neurooncol 141:327–335. https://doi.org/10.1007/s11060-018-03034-6
doi: 10.1007/s11060-018-03034-6
pubmed: 30536195
van Lent DI, van Baarsen KM, Snijders TJ, Robe PAJT (2020) Radiological differences between subtypes of WHO 2016 grade II-III gliomas: a systematic review and meta-analysis. Neuro Oncol Adv 2:vdaa04
Choi C, Ganji SK, DeBerardinis RJ et al (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18:624–629. https://doi.org/10.1038/nm.2682
doi: 10.1038/nm.2682
pubmed: 22281806
pmcid: 3615719
Broen MPG, Smits M, Wijnenga MMJ et al (2018) The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol 20:1393–1399. https://doi.org/10.1093/neuonc/noy048
doi: 10.1093/neuonc/noy048
pubmed: 29590424
pmcid: 6120363
Patel SH, Poisson LM, Brat DJ et al (2017) T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: A TCGA/TCIA project. Clin Cancer Res 23:6078–6085. https://doi.org/10.1158/1078-0432.CCR-17-0560
doi: 10.1158/1078-0432.CCR-17-0560
pubmed: 28751449
Foltyn M, Nieto Taborda KN, Neuberger U et al (2020) T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology. Neuro Oncol Adv 2:vdaa004
doi: 10.1093/noajnl/vdaa004
Meyronet D, Esteban-Mader M, Bonnet C et al (2017) Characteristics of H3 K27M-mutant gliomas in adults. Neuro Oncol 19:1127–1134. https://doi.org/10.1093/neuonc/now274
doi: 10.1093/neuonc/now274
pubmed: 28201752
pmcid: 5570304
Labussière M, Boisselier B, Mokhtari K et al (2014) Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology 83:1200–1206. https://doi.org/10.1212/WNL.0000000000000814
doi: 10.1212/WNL.0000000000000814
pubmed: 25150284
Simon M, Hosen I, Gousias K et al (2015) TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol 17:45–52. https://doi.org/10.1093/neuonc/nou158
doi: 10.1093/neuonc/nou158
pubmed: 25140036
Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174
doi: 10.2307/2529310
pubmed: 843571
Tesileanu CMS, Dirven L, Wijnenga MMJ et al (2020) Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-now criteria. Neuro Oncol 22:515–523. https://doi.org/10.1093/neuonc/noz200
doi: 10.1093/neuonc/noz200
pubmed: 31637414
Lee D, Riestenberg RA, Haskell-Mendoza A, Bloch O (2021) Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV: a single-institution case series and review. J Neurooncol 152:89–98. https://doi.org/10.1007/s11060-020-03677-4
doi: 10.1007/s11060-020-03677-4
pubmed: 33389563
Aoki K, Nakamura H, Suzuki H et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20:66–77. https://doi.org/10.1093/neuonc/nox132
doi: 10.1093/neuonc/nox132
pubmed: 29016839
Lasocki A, Gaillard F, Tacey MA et al (2016) The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma. J Neurooncol 129:471–478. https://doi.org/10.1007/s11060-016-2193-y
doi: 10.1007/s11060-016-2193-y
pubmed: 27412000
Benouaich-Amiel A, Khasminsky V, Gal O et al (2021) Multicentric non-enhancing lesions in glioblastoma: a retrospective study. J Clin Neurosci 85:20–26. https://doi.org/10.1016/j.jocn.2020.11.050
doi: 10.1016/j.jocn.2020.11.050
pubmed: 33581785
Lasocki A, Gaillard F, Tacey M et al (2016) Incidence and prognostic significance of non-enhancing cortical signal abnormality in glioblastoma. J Med Imaging Radiat Oncol 60:66–73. https://doi.org/10.1111/1754-9485.12421
doi: 10.1111/1754-9485.12421
pubmed: 26597591
Patel SH, Batchala PP, Muttikkal TJE et al (2021) Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI marker for isocitrate dehydrogenase (IDH) mutation in glioblastoma. J Neurooncol 152:523–531. https://doi.org/10.1007/s11060-021-03720-y
doi: 10.1007/s11060-021-03720-y
pubmed: 33661425
Lasocki A, Gaillard F, Tacey M et al (2018) Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival. J Clin Neurosci 47:168–173. https://doi.org/10.1016/j.jocn.2017.09.007
doi: 10.1016/j.jocn.2017.09.007
pubmed: 28988652
Milano MT, Okunieff P, Donatello RS et al (2010) Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 78:1147–1155. https://doi.org/10.1016/j.ijrobp.2009.09.018
doi: 10.1016/j.ijrobp.2009.09.018
pubmed: 20207495
Brandes AA, Tosoni A, Franceschi E et al (2009) Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol 27:1275–1279. https://doi.org/10.1200/JCO.2008.19.4969
doi: 10.1200/JCO.2008.19.4969
pubmed: 19188675
Lahmi L, Idbaih A, Rivin Del Campo E et al (2019) Whole brain radiotherapy with concurrent temozolomide in multifocal and/or multicentric newly diagnosed glioblastoma. J Clin Neurosci 68:39–44. https://doi.org/10.1016/j.jocn.2019.07.065
doi: 10.1016/j.jocn.2019.07.065
pubmed: 31399318
Showalter TN, Andrel J, Andrews DW et al (2007) Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys 69:820–824. https://doi.org/10.1016/j.ijrobp.2007.03.045
doi: 10.1016/j.ijrobp.2007.03.045
pubmed: 17499453
Scherer HJ (1938) Structural development in gliomas. Am J Cancer 34:333–351